Literature DB >> 18646347

AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.

Angel M Mayor1, María A Gómez, Eddy Ríos-Olivares, Robert F Hunter-Mellado.   

Abstract

INTRODUCTION: Malignant disorders have been linked to the HIV epidemic from its onset. Implementation of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the HIV/AIDS morbidity and mortality. The present study evaluates the neoplasm prevalence before and after the implementation of HAART.
METHODS: A cross-sectional study was conducted in 171 HIV-infected adults who were followed in Puerto Rico from May 1992 through December 2005. Neoplasm prevalence was measured, and the difference in AIDS- and non-AIDS-defining neoplasms was analyzed before and after the HAART era. Between-group differences were explored by using chi2, Fisher exact test, analysis of variance, and student t test.
RESULTS: Malignant neoplasms were detected in 171 patients (4.8%). Of these, 51.5% were AIDS-defining neoplasms, and 68% were established before HAART. AIDS-defining neoplasms accounted for 62.4% of those detected before the availability of HAART and 25.9% of those detected after HAART. Except for cervical carcinoma, the prevalence of AIDS-defining neoplasms decreased after HAART. Non-AIDS lymphomas and prostate neoplasms were more frequent after HAART. DISCUSSION: Our study found a significant reduction of Kaposi sarcoma and AIDS-related lymphoma in the HAART era of the AIDS epidemic. A higher prevalence of non-AIDS-defining lymphomas, prostate carcinoma, and cervical carcinoma was seen in the HAART era. These findings suggest that factors other than severe immunosuppression are involved in the neoplasms' pathogenesis. Preventive strategies that include screening tests, vaccination, and lifestyle modification should be routinely applied in HIV-infected patients.

Entities:  

Mesh:

Year:  2008        PMID: 18646347      PMCID: PMC3546505     

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  19 in total

1.  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.

Authors: 
Journal:  MMWR Suppl       Date:  1987-08-14

2.  Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer?

Authors:  Mark Bower; Danish Mazhar; Justin Stebbing
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

3.  Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population.

Authors:  C Lewden; F Raffi; G Chêne; A Sobel; C Leport
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

Review 4.  The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.

Authors:  G Gaidano; D Capello; A Carbone
Journal:  Semin Oncol       Date:  2000-08       Impact factor: 4.929

5.  Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.

Authors:  Judith E Sackoff; David B Hanna; Melissa R Pfeiffer; Lucia V Torian
Journal:  Ann Intern Med       Date:  2006-09-19       Impact factor: 25.391

6.  Immune restoration with antiretroviral therapies: implications for clinical management.

Authors:  M M Lederman; H Valdez
Journal:  JAMA       Date:  2000-07-12       Impact factor: 56.272

7.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2000-11-15       Impact factor: 13.506

8.  Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum.

Authors:  Monica S Webb; Peter A Vanable; Michael P Carey; Donald C Blair
Journal:  J Behav Med       Date:  2007-06-15

Review 9.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

Review 10.  AIDS malignancies in the era of highly active antiretroviral therapy.

Authors:  Amy E Gates; Lawrence D Kaplan
Journal:  Oncology (Williston Park)       Date:  2002-05       Impact factor: 2.990

View more
  5 in total

Review 1.  The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.

Authors:  Alfred O Ankrah; Andor W J M Glaudemans; Hans C Klein; Rudi A J O Dierckx; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-05-25

Review 2.  Positron emission tomography in patients suffering from HIV-1 infection.

Authors:  Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

Review 3.  Urologic complications of HIV and AIDS.

Authors:  Chris F Heyns; Adam E Groeneveld; Nelson B Sigarroa
Journal:  Nat Clin Pract Urol       Date:  2009-01

Review 4.  Evolving spectrum and incidence of non-AIDS-defining malignancies.

Authors:  Liron Pantanowitz; Bruce J Dezube
Journal:  Curr Opin HIV AIDS       Date:  2009-01       Impact factor: 4.283

Review 5.  Resistance profiles to antifungal agents in Candida albicans isolated from human oral cavities: systematic review and meta-analysis.

Authors:  Sarah Quadros Santos Kessler; Pauline Mastella Lang; Tatiane Silva Dal-Pizzol; Francisco Montagner
Journal:  Clin Oral Investig       Date:  2022-09-27       Impact factor: 3.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.